Organic Letters
Letter
(16) (a) Tyrra, W.; Naumann, D.; Hoge, B.; Yagupolskii, Y. L. J.
Fluorine Chem. 2003, 119, 101. (b) Yin, G.; Kalvet, I.; Schoenebeck, F.
Angew. Chem., Int. Ed. 2015, 54, 6809.
(17) Tavener, S. J.; Adams, D. J.; Clark, J. H. J. Fluorine Chem. 1999,
95, 171.
(18) Preservation of chiral integrity is claimed based on measurement
of optical rotations of chiral products (see the SI) and comparison
with literature data (ref 21). Accurate optical rotation for known
compound 2o was measured with a variance of 2% compared to ref
21. Accordingly, we assume that optical rotations measured for all new
single-enantiomer products 2a−f and 2n−q are indicative of
enantiopurity.
(19) Luo, J.; Zhu, Z.; Liu, Y.; Zhao, X. Org. Lett. 2015, 17, 3620.
(20) For stereospecific ring opening, see, for example, ref 14a, b and:
́ ́
(a) Mata, L.; Jimenez-Oses, G.; Avenoza, A.; Busto, J. H.; Peregrina, J.
M. J. Org. Chem. 2011, 76, 4034. For a racemizing process, see:
(b) Wei, L.; Lubell, W. D. Org. Lett. 2000, 2, 2595. (c) Wei, L.; Lubell,
W. D. Can. J. Chem. 2001, 79, 94. The assigned trans stereochemical
relationship in 2r is based on the assumed inversion of configuration at
the β-carbon.
tion of China (Nos. 21225208, 21472137, and 21532008), and
the National Basic Research Program of China (973 Program:
2014CB745100). H.C. thanks the French “Minister
Recherche et de l’Enseignement Superieur” for a doctoral
fellowship.
̀
e de la
́
REFERENCES
■
(1) (a) Kitevski-LeBlanc, J. L.; Prosser, R. S. Prog. Nucl. Magn. Reson.
Spectrosc. 2012, 62, 1. (b) Chen, H.; Viel, S.; Ziarelli, F.; Peng, L.
Chem. Soc. Rev. 2013, 42, 7971. (c) Dolbier, W. R., Jr. Guide to Fluorine
NMR for Organic Chemists; Wiley: Hoboken, 2016. (d) Arntson, K. E.;
Pomerantz, W. C. K. J. Med. Chem. 2016, 59, 5158. (e) Marsh, E. N.
G.; Suzuki, Y. ACS Chem. Biol. 2014, 9, 1242.
(2) (a) Qiu, X.-L.; Meng, W.-D.; Qing, F.-L. Tetrahedron 2004, 60,
6711. (b) Qiu, X.-L.; Qing, F.-L. Eur. J. Org. Chem. 2011, 2011, 3261.
(c) Salwiczek, M.; Nyakatura, E. K.; Gerling, U. I. M.; Ye, S.; Koksch,
B. Chem. Soc. Rev. 2012, 41, 2135. (d) Marsh, E. N. G. Acc. Chem. Res.
2014, 47, 2878. (e) Vaughan, M. D.; Su, Z.; Daub, E.; Honek, J. F. Org.
Biomol. Chem. 2016, 14, 8942.
(3) (a) Toulgoat, F.; Alazet, S.; Billard, T. Eur. J. Org. Chem. 2014,
2014, 2415. (b) Xu, X.-H.; Matsuzaki, K.; Shibata, N. Chem. Rev. 2015,
115, 731. (c) Chachignon, H.; Cahard, D. Chin. J. Chem. 2016, 34,
445. (d) Barata-Vallejo, S.; Bonesi, S.; Postigo, A. Org. Biomol. Chem.
2016, 14, 7150.
(21) Tripeptides featuring internal S-(trifluoromethyl)-L-cysteine or
L-trifluoromethionine were recently prepared by using Langlois’
procedure (ref 8) or Togni’s reagent (ref 6). Gadais, C.; Saraiva-
Rosa, N.; Chelain, E.; Pytkowicz, J.; Brigaud, T. Eur. J. Org. Chem.
2017, 2017, 246.
(4) (a) Houston, M. E., Jr.; Honek, J. F. J. Chem. Soc., Chem.
Commun. 1989, 761. (b) Soloshonok, V.; Kukhar, V.; Pustovit, Y.;
Nazaretian, V. Synlett 1992, 1992, 657.
(5) Bottecchia, C.; Wei, X.-J.; Kuijpers, K. P. L.; Hessel, V.; Noel, T. J.
̈
Org. Chem. 2016, 81, 7301.
(6) (a) Kieltsch, I.; Eisenberger, P.; Togni, A. Angew. Chem., Int. Ed.
2007, 46, 754. (b) Capone, S.; Kieltsch, I.; Flogel, O.; Lelais, G.;
̈
Togni, A.; Seebach, D. Helv. Chim. Acta 2008, 91, 2035.
(7) Umemoto, T.; Ando, A. Bull. Chem. Soc. Jpn. 1986, 59, 447.
(8) Langlois, B.; Monteg
63.
̀
re, D.; Roidot, N. J. Fluorine Chem. 1994, 68,
(9) Yasui, H.; Yamamoto, T.; Tokunaga, E.; Shibata, N. J. Fluorine
Chem. 2011, 132, 186.
(10) Billard, T.; Roques, N.; Langlois, B. R. J. Org. Chem. 1999, 64,
3813.
(11) Guo, S.; Zhang, X.; Tang, P. Angew. Chem., Int. Ed. 2015, 54,
4065.
(12) Mukherjee, S.; Maji, B.; Tlahuext-Aca, A.; Glorius, F. J. Am.
Chem. Soc. 2016, 138, 16200.
(13) (a) Melendez, R. E.; Lubell, W. D. Tetrahedron 2003, 59, 2581.
́
(b) Rashid Baig, N. B.; Chandrakala, R. N.; Sudhir, V. S.;
Chandrasekaran, S. J. Org. Chem. 2010, 75, 2910. (c) Nasir Baig, R.
B.; Nadagouda, M. N.; Varma, R. S. Aldrichimica Acta 2015, 48, 71.
(14) For nucleophilic fluorination of sulfamidates, see, for example:
(a) Lyle, T. A.; Magill, C. A.; Pitzenberger, S. M. J. Am. Chem. Soc.
1987, 109, 7890. (b) Van Dort, M. E.; Jung, Y. W.; Sherman, P. S.;
Kilbourn, M. R.; Wieland, D. M. J. Med. Chem. 1995, 38, 810.
(c) Posakony, J. J.; Tewson, T. J. Synthesis 2002, 2002, 766.
́ ́
(d) Avenoza, A.; Busto, J. H.; Corzana, F.; Jimenez-Oses, G.;
Peregrina, J. M. Chem. Commun. 2004, 980. (e) Nishimura, T.; Ebe,
Y.; Fujimoto, H.; Hayashi, T. Chem. Commun. 2013, 49, 5504.
(f) Huang, C.; Yuan, L.; Rich, K. M.; McConathy, J. Nucl. Med. Biol.
2013, 40, 498. For nucleophilic fluoroalkylation of sulfamidates, see:
(g) Ni, C.; Liu, J.; Zhang, L.; Hu, J. Angew. Chem., Int. Ed. 2007, 46,
786. For ring-opening of sulfamidates with sulfur nucleophiles, see ref
13a and: (h) Baldwin, J. E.; Spivey, A. C.; Schofield, C. J. Tetrahedron:
Asymmetry 1990, 1, 881. (i) Cohen, S. B.; Halcomb, R. L. Org. Lett.
2001, 3, 405. (j) Cohen, S. B.; Halcomb, R. L. J. Am. Chem. Soc. 2002,
124, 2534. (k) Cobb, S. L.; Vederas, J. C. Org. Biomol. Chem. 2007, 5,
1031.
(15) (a) Chen, C.; Chu, L.; Qing, F.-L. J. Am. Chem. Soc. 2012, 134,
12454. (b) Dai, X.; Cahard, D. Synlett 2015, 26, 40.
D
Org. Lett. XXXX, XXX, XXX−XXX